EndoChoice Holdings Release: New Clinical Evidence To Be Presented On The Fuse Full Spectrum Endoscopy System At DDW 2016
ALPHARETTA, Ga., May 4, 2016 /PRNewswire/ -- EndoChoice Holdings, Inc. (NYSE: GI) announced that the Company will participate at the Digestive Disease Week (DDW®) tradeshow, May 22-24 in San Diego, CA. The EndoChoice booth will be #4317. Products from EndoChoice's Imaging, Devices, Diagnostics, and Infection Control portfolios will be on display and available for hands-on demonstration at EndoChoice's booth throughout the entire week.
"Several studies being presented at this year's DDW highlight the growing library of clinical evidence showing the positive impact that Fuse has on clinical outcomes" said Mark Gilreath, founder and CEO at EndoChoice.
One of the studies from Mount Sinai and Carnegie Hill Endoscopy in New York, compared the last months of use of a traditional forward viewing colonoscope to the first months with the Generation 2 Fuse colonoscope. Overall, the study included 25 physicians and 4,163 patients and found that the Adenoma Detection Rate (ADR) with traditional colonoscopes was 23.5%, while Fuse delivered a 28.9% ADR, which is an increase of 23% (p<0.001). This included more polyps in the right colon and more polyps per colon using the Fuse system.
Per the senior author, Blair Lewis M.D., "Our study was designed to look at the impact that Fuse has in the day to day practice in a busy endoscopy center, among skilled endoscopists. We know from previous Kaiser data, published in the New England Journal, that for every 1% increase in ADR, we should expect a 3% decrease in interval cancers, and a 5% decrease in mortality from interval cancer. Translated to our Center, we will have decreased interval cancers by 16% and interval mortality by 27%. For the first time, we have real life experience showing a truly significant improvement in ADR using Fuse."
"It seems obvious that seeing more with Fuse will yield better outcomes for patients. This large study showing a significant increase in the detection of precancerous polyps simply validates the positive feedback we receive each week from Fuse users around the world" said Mark Gilreath, founder and CEO at EndoChoice.
Reference for the study:
Benjamin Nulsen, Ryan C. Ungaro, Natalie Davis, Melinda Lugay, Blair S. Lewis
Gastroenterology, Vol. 150, Issue 4, S756 Published in issue: April 2016
About DDW
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW take place May 21-24, 2016, at the San Diego Convention Center, San Diego, CA. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org
About EndoChoice
Based near Atlanta, Georgia, EndoChoice® (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy® (Fuse®) system. EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.
For more information on Fuse: www.endochoice.com/fuse or www.fusecolonoscopy.org
For more information, press only:
Company Contact:
David Gill, President & CFO
678-585-1040
david.gill@endochoice.com
Investor Contacts:
Nick Laudico or Zack Kubow
The Ruth Group
646-536-7030 / 7020
nlaudico@theruthgroup.com
zkubow@theruthgroup.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-clinical-evidence-to-be-presented-on-the-fuse-full-spectrum-endoscopy-system-at-ddw-2016-300262548.html
SOURCE EndoChoice Holdings, Inc.
